Genzyme gets cold tissue welding technology:
This article was originally published in Clinica
Executive Summary
Genzyme Tissue Repair will get exclusive rights for the development and commercialisation of PhotoBioMed's photoactive tissue welding technology for all orthopaedic purposes. Genzyme will make an initial payment to the Dallas-based company and subsequent milestone and royalty payments. PhotoBioMed's technology uses a photochemical compound which, when light activated, interacts with collagen fibres in the tissue, cross-linking the proteins and welding torn tissue without heat. Genzyme, of Cambridge, Massachusetts, will first develop applications for meniscal repair.